Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinal Detachment | 19 | 2019 | 87 | 3.170 |
Why?
|
| Vitrectomy | 18 | 2012 | 112 | 2.650 |
Why?
|
| Retinopathy of Prematurity | 11 | 2019 | 58 | 2.340 |
Why?
|
| Vitreous Body | 22 | 2008 | 116 | 2.120 |
Why?
|
| Triamcinolone Acetonide | 7 | 2008 | 37 | 1.730 |
Why?
|
| Retina | 11 | 2019 | 543 | 1.620 |
Why?
|
| Retinal Perforations | 6 | 2019 | 27 | 1.520 |
Why?
|
| Endophthalmitis | 8 | 2008 | 82 | 1.290 |
Why?
|
| Laser Coagulation | 6 | 2010 | 142 | 1.040 |
Why?
|
| Lens, Crystalline | 7 | 2012 | 163 | 1.000 |
Why?
|
| Visual Acuity | 15 | 2019 | 865 | 1.000 |
Why?
|
| Injections | 14 | 2008 | 286 | 0.990 |
Why?
|
| Glucocorticoids | 5 | 2007 | 617 | 0.880 |
Why?
|
| Electroretinography | 8 | 2010 | 127 | 0.860 |
Why?
|
| Refraction, Ocular | 2 | 2010 | 300 | 0.590 |
Why?
|
| Aza Compounds | 3 | 2006 | 25 | 0.580 |
Why?
|
| Anti-Infective Agents | 4 | 2008 | 466 | 0.550 |
Why?
|
| Eye Infections, Fungal | 3 | 2008 | 79 | 0.520 |
Why?
|
| Fluoroquinolones | 5 | 2006 | 135 | 0.520 |
Why?
|
| Eye Infections, Bacterial | 3 | 2008 | 96 | 0.500 |
Why?
|
| Aqueous Humor | 6 | 2006 | 31 | 0.480 |
Why?
|
| Retinal Vein Occlusion | 2 | 2008 | 29 | 0.480 |
Why?
|
| Gram-Positive Bacterial Infections | 3 | 2008 | 163 | 0.480 |
Why?
|
| Quinolines | 3 | 2006 | 402 | 0.450 |
Why?
|
| Fluorescein Angiography | 7 | 2019 | 150 | 0.420 |
Why?
|
| Retinal Diseases | 4 | 2006 | 192 | 0.420 |
Why?
|
| Antifungal Agents | 5 | 2010 | 880 | 0.420 |
Why?
|
| Myopia | 2 | 2010 | 196 | 0.380 |
Why?
|
| Rabbits | 7 | 2008 | 1028 | 0.380 |
Why?
|
| Macular Degeneration | 4 | 2008 | 121 | 0.380 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2011 | 1269 | 0.370 |
Why?
|
| Triazoles | 3 | 2004 | 627 | 0.370 |
Why?
|
| Retinal Hemorrhage | 3 | 2011 | 24 | 0.370 |
Why?
|
| Vitreous Detachment | 2 | 2007 | 15 | 0.350 |
Why?
|
| Preservatives, Pharmaceutical | 2 | 2007 | 14 | 0.350 |
Why?
|
| Suture Techniques | 2 | 2008 | 292 | 0.330 |
Why?
|
| Ectopia Lentis | 1 | 2008 | 12 | 0.310 |
Why?
|
| Bacillus cereus | 1 | 2008 | 12 | 0.310 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2008 | 74 | 0.300 |
Why?
|
| Cryotherapy | 2 | 2006 | 67 | 0.300 |
Why?
|
| Iris | 1 | 2008 | 73 | 0.300 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2008 | 188 | 0.280 |
Why?
|
| Chromatography, High Pressure Liquid | 6 | 2008 | 590 | 0.280 |
Why?
|
| Benzyl Alcohol | 1 | 2006 | 2 | 0.280 |
Why?
|
| Retinal Neovascularization | 1 | 2006 | 19 | 0.280 |
Why?
|
| Pharmaceutical Vehicles | 1 | 2006 | 13 | 0.280 |
Why?
|
| Lens Implantation, Intraocular | 2 | 2008 | 340 | 0.270 |
Why?
|
| Gestational Age | 7 | 2006 | 1173 | 0.270 |
Why?
|
| Fovea Centralis | 1 | 2006 | 10 | 0.270 |
Why?
|
| Tomography, Optical Coherence | 4 | 2017 | 550 | 0.270 |
Why?
|
| Telangiectasis | 1 | 2006 | 21 | 0.270 |
Why?
|
| Retinal Vessels | 2 | 2003 | 82 | 0.260 |
Why?
|
| Cat-Scratch Disease | 1 | 2005 | 34 | 0.250 |
Why?
|
| Postoperative Complications | 7 | 2009 | 5681 | 0.240 |
Why?
|
| Infant, Newborn | 11 | 2012 | 8699 | 0.240 |
Why?
|
| Phacoemulsification | 2 | 2005 | 235 | 0.240 |
Why?
|
| Triamcinolone | 1 | 2004 | 24 | 0.230 |
Why?
|
| Lenses, Intraocular | 1 | 2008 | 394 | 0.220 |
Why?
|
| Photochemotherapy | 1 | 2003 | 116 | 0.210 |
Why?
|
| Pyrimidines | 3 | 2004 | 3669 | 0.210 |
Why?
|
| Papilledema | 1 | 2003 | 87 | 0.210 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2011 | 1580 | 0.210 |
Why?
|
| Infant, Very Low Birth Weight | 5 | 2006 | 171 | 0.210 |
Why?
|
| Retrospective Studies | 19 | 2019 | 39890 | 0.200 |
Why?
|
| Choroid | 2 | 2017 | 42 | 0.190 |
Why?
|
| Osmolar Concentration | 3 | 2008 | 202 | 0.190 |
Why?
|
| Mitosporic Fungi | 1 | 2001 | 19 | 0.190 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2006 | 1076 | 0.190 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2001 | 22 | 0.190 |
Why?
|
| Alcaligenes | 1 | 2000 | 3 | 0.180 |
Why?
|
| Propionibacterium acnes | 1 | 2000 | 24 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 4 | 2008 | 3187 | 0.180 |
Why?
|
| Retinal Artery Occlusion | 1 | 2000 | 17 | 0.180 |
Why?
|
| Prednisolone | 1 | 2001 | 132 | 0.180 |
Why?
|
| Biological Availability | 4 | 2006 | 225 | 0.180 |
Why?
|
| Male | 30 | 2019 | 128315 | 0.180 |
Why?
|
| Keratitis | 1 | 2001 | 125 | 0.170 |
Why?
|
| Pseudophakia | 1 | 2000 | 72 | 0.170 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2000 | 63 | 0.170 |
Why?
|
| Eye Diseases, Hereditary | 1 | 1999 | 36 | 0.160 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2000 | 170 | 0.160 |
Why?
|
| Humans | 42 | 2019 | 270740 | 0.160 |
Why?
|
| Treatment Outcome | 12 | 2012 | 33737 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 4481 | 0.150 |
Why?
|
| Fundus Oculi | 3 | 2019 | 69 | 0.150 |
Why?
|
| Follow-Up Studies | 7 | 2012 | 15218 | 0.150 |
Why?
|
| Postoperative Period | 2 | 2009 | 666 | 0.140 |
Why?
|
| Mycoses | 1 | 2001 | 393 | 0.140 |
Why?
|
| Half-Life | 2 | 2008 | 269 | 0.140 |
Why?
|
| Female | 24 | 2019 | 148940 | 0.140 |
Why?
|
| Intraocular Pressure | 2 | 2008 | 156 | 0.140 |
Why?
|
| Acute Disease | 3 | 2007 | 2493 | 0.140 |
Why?
|
| Choroidal Neovascularization | 2 | 2008 | 30 | 0.130 |
Why?
|
| Disease Progression | 4 | 2019 | 6867 | 0.120 |
Why?
|
| Voriconazole | 3 | 2004 | 115 | 0.120 |
Why?
|
| Exudates and Transudates | 3 | 2011 | 56 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2004 | 2156 | 0.120 |
Why?
|
| Birth Weight | 2 | 2006 | 355 | 0.120 |
Why?
|
| Animals | 12 | 2010 | 61956 | 0.120 |
Why?
|
| Aged | 15 | 2019 | 73333 | 0.120 |
Why?
|
| Blindness | 2 | 2008 | 80 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 2004 | 6390 | 0.110 |
Why?
|
| Thrombolytic Therapy | 1 | 2015 | 250 | 0.110 |
Why?
|
| Resuscitation | 1 | 2015 | 274 | 0.100 |
Why?
|
| Central Serous Chorioretinopathy | 1 | 2011 | 7 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2015 | 6224 | 0.100 |
Why?
|
| Adult | 13 | 2019 | 82040 | 0.090 |
Why?
|
| Pulmonary Embolism | 1 | 2015 | 342 | 0.090 |
Why?
|
| Aged, 80 and over | 10 | 2017 | 30998 | 0.090 |
Why?
|
| Rats | 3 | 2004 | 6441 | 0.090 |
Why?
|
| Heart Arrest | 1 | 2015 | 382 | 0.090 |
Why?
|
| Administration, Oral | 3 | 2004 | 1608 | 0.090 |
Why?
|
| Child, Preschool | 4 | 2012 | 17061 | 0.090 |
Why?
|
| Emergency Medical Services | 1 | 2015 | 470 | 0.090 |
Why?
|
| Echinocandins | 1 | 2010 | 134 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2008 | 2345 | 0.080 |
Why?
|
| Sulfur Hexafluoride | 1 | 2008 | 6 | 0.080 |
Why?
|
| Bacteria | 2 | 2005 | 654 | 0.080 |
Why?
|
| Epiretinal Membrane | 1 | 2008 | 15 | 0.080 |
Why?
|
| Critical Care | 1 | 2015 | 796 | 0.080 |
Why?
|
| Middle Aged | 12 | 2019 | 90352 | 0.080 |
Why?
|
| Vancomycin | 2 | 2008 | 292 | 0.080 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2008 | 74 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2011 | 3409 | 0.080 |
Why?
|
| Bevacizumab | 2 | 2011 | 967 | 0.070 |
Why?
|
| Eye | 1 | 2009 | 283 | 0.070 |
Why?
|
| Child | 6 | 2019 | 30559 | 0.070 |
Why?
|
| Posture | 1 | 2008 | 190 | 0.070 |
Why?
|
| Biometry | 1 | 2009 | 250 | 0.070 |
Why?
|
| Crack Cocaine | 1 | 2007 | 5 | 0.070 |
Why?
|
| Citrus | 1 | 2007 | 8 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2006 | 5056 | 0.070 |
Why?
|
| Ceftazidime | 1 | 2008 | 66 | 0.070 |
Why?
|
| Incidence | 3 | 2007 | 5824 | 0.070 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2007 | 47 | 0.070 |
Why?
|
| Macular Edema | 2 | 2006 | 90 | 0.070 |
Why?
|
| Intraoperative Care | 1 | 2008 | 274 | 0.070 |
Why?
|
| Myocardial Infarction | 1 | 2015 | 1181 | 0.070 |
Why?
|
| Dark Adaptation | 1 | 2006 | 37 | 0.070 |
Why?
|
| Aphakia, Postcataract | 1 | 2006 | 20 | 0.070 |
Why?
|
| Cataract | 1 | 2008 | 236 | 0.070 |
Why?
|
| Vimentin | 1 | 2007 | 252 | 0.060 |
Why?
|
| Vision, Ocular | 1 | 2006 | 134 | 0.060 |
Why?
|
| Silicone Oils | 1 | 2005 | 13 | 0.060 |
Why?
|
| Serpins | 1 | 2006 | 72 | 0.060 |
Why?
|
| Bartonella henselae | 1 | 2005 | 22 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 9039 | 0.060 |
Why?
|
| Nerve Growth Factors | 1 | 2006 | 128 | 0.060 |
Why?
|
| Photic Stimulation | 1 | 2006 | 272 | 0.060 |
Why?
|
| Florida | 1 | 2005 | 116 | 0.060 |
Why?
|
| Risk Factors | 4 | 2007 | 17888 | 0.060 |
Why?
|
| Retinal Degeneration | 1 | 2006 | 97 | 0.060 |
Why?
|
| Laser Therapy | 1 | 2009 | 466 | 0.060 |
Why?
|
| Fluorocarbons | 1 | 2005 | 64 | 0.060 |
Why?
|
| Time Factors | 4 | 2019 | 13006 | 0.060 |
Why?
|
| Neuroglia | 1 | 2007 | 248 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 451 | 0.060 |
Why?
|
| Candidiasis | 1 | 2007 | 278 | 0.060 |
Why?
|
| Cocaine-Related Disorders | 1 | 2007 | 238 | 0.060 |
Why?
|
| Photography | 1 | 2005 | 125 | 0.060 |
Why?
|
| Ophthalmic Solutions | 1 | 2004 | 97 | 0.060 |
Why?
|
| Eye Proteins | 1 | 2006 | 275 | 0.060 |
Why?
|
| Porphyrins | 1 | 2003 | 39 | 0.060 |
Why?
|
| Gases | 1 | 2003 | 39 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 4831 | 0.060 |
Why?
|
| Photosensitizing Agents | 1 | 2003 | 82 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2005 | 418 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2004 | 726 | 0.050 |
Why?
|
| Coloring Agents | 1 | 2003 | 233 | 0.050 |
Why?
|
| Enterococcus faecium | 1 | 2003 | 48 | 0.050 |
Why?
|
| Vancomycin Resistance | 1 | 2003 | 60 | 0.050 |
Why?
|
| Indocyanine Green | 1 | 2003 | 125 | 0.050 |
Why?
|
| Spherocytes | 1 | 2002 | 4 | 0.050 |
Why?
|
| Lens Subluxation | 1 | 2002 | 4 | 0.050 |
Why?
|
| Scleral Buckling | 1 | 2002 | 14 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2005 | 430 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2004 | 1049 | 0.050 |
Why?
|
| Necrosis | 1 | 2003 | 595 | 0.050 |
Why?
|
| Prospective Studies | 4 | 2006 | 13414 | 0.050 |
Why?
|
| Corneal Injuries | 1 | 2001 | 31 | 0.050 |
Why?
|
| Young Adult | 3 | 2019 | 22251 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2006 | 1857 | 0.040 |
Why?
|
| Debridement | 1 | 2001 | 121 | 0.040 |
Why?
|
| Hematologic Diseases | 1 | 2002 | 255 | 0.040 |
Why?
|
| Macrophages | 1 | 2007 | 1350 | 0.040 |
Why?
|
| Intravitreal Injections | 2 | 2011 | 145 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2002 | 482 | 0.040 |
Why?
|
| Cataract Extraction | 1 | 2002 | 212 | 0.040 |
Why?
|
| Ophthalmology | 1 | 2002 | 207 | 0.040 |
Why?
|
| Microphthalmos | 1 | 1999 | 65 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2006 | 1716 | 0.040 |
Why?
|
| Device Removal | 1 | 2000 | 339 | 0.040 |
Why?
|
| Hyperplasia | 1 | 1999 | 564 | 0.040 |
Why?
|
| Eye Neoplasms | 1 | 2000 | 257 | 0.040 |
Why?
|
| Infarction | 1 | 2017 | 35 | 0.040 |
Why?
|
| Bacteremia | 1 | 2003 | 721 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2004 | 1690 | 0.030 |
Why?
|
| Mycosis Fungoides | 1 | 2000 | 341 | 0.030 |
Why?
|
| Macula Lutea | 1 | 2017 | 46 | 0.030 |
Why?
|
| Giant Cell Arteritis | 1 | 2017 | 63 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 7655 | 0.030 |
Why?
|
| Adolescent | 2 | 2019 | 32767 | 0.030 |
Why?
|
| Biomarkers | 1 | 2007 | 5051 | 0.030 |
Why?
|
| Germany | 1 | 2015 | 123 | 0.030 |
Why?
|
| Infant | 2 | 2012 | 13999 | 0.030 |
Why?
|
| Texas | 1 | 2005 | 6449 | 0.030 |
Why?
|
| Vitreous Hemorrhage | 2 | 2005 | 10 | 0.030 |
Why?
|
| Ultrasonography | 1 | 1999 | 1933 | 0.030 |
Why?
|
| Subretinal Fluid | 1 | 2011 | 11 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2002 | 1452 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2015 | 727 | 0.020 |
Why?
|
| Lipopeptides | 1 | 2010 | 117 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 497 | 0.020 |
Why?
|
| Retinal Ganglion Cells | 1 | 2010 | 164 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2000 | 3949 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 7100 | 0.020 |
Why?
|
| Beverages | 1 | 2007 | 104 | 0.020 |
Why?
|
| Tonometry, Ocular | 1 | 2006 | 31 | 0.020 |
Why?
|
| Urine | 1 | 2006 | 135 | 0.020 |
Why?
|
| Sputum | 1 | 2006 | 157 | 0.020 |
Why?
|
| Models, Animal | 1 | 2006 | 657 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2000 | 4895 | 0.010 |
Why?
|
| Eye Enucleation | 1 | 2003 | 87 | 0.010 |
Why?
|
| Fungi | 1 | 2004 | 147 | 0.010 |
Why?
|
| Biological Transport | 1 | 2004 | 626 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2015 | 9470 | 0.010 |
Why?
|
| Survival Rate | 1 | 2015 | 12541 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2006 | 1497 | 0.010 |
Why?
|
| Choroid Neoplasms | 1 | 2000 | 45 | 0.010 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2000 | 34 | 0.010 |
Why?
|
| Cryosurgery | 1 | 2002 | 196 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2002 | 822 | 0.010 |
Why?
|
| Mice | 2 | 2010 | 35600 | 0.010 |
Why?
|
| Reoperation | 1 | 2002 | 1392 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2002 | 870 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2000 | 1726 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2002 | 1325 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2000 | 3045 | 0.010 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2002 | 2635 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2000 | 16689 | 0.000 |
Why?
|